Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Medtronic
Express Scripts

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Entinostat

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Entinostat: Sponsors, patents, clinical trial progress

Entinostat is an investigational drug.

There have been 62 clinical trials for Entinostat. The most recent clinical trial was a Phase 2 trial, which was initiated on May 15th 2018.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are Syndax Pharmaceuticals, National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.

There are one hundred and forty-five US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Entinostat
TitleSponsorPhase
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder CancerUNC Lineberger Comprehensive Cancer CenterPhase 2
Molibresib and Entinostat in Treating Patients With Advanced or Refractory Solid Tumors or LymphomasNational Cancer Institute (NCI)Phase 1
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersAstraZenecaPhase 1/Phase 2

See all Entinostat clinical trials

Clinical Trial Summary for Entinostat

Top disease conditions for Entinostat
Top clinical trial sponsors for Entinostat

See all Entinostat clinical trials

US Patents for Entinostat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Entinostat   See Pricing Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   See Pricing
Entinostat   See Pricing Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III Frequency Therapeutics, Inc. (Woburn, MA)   See Pricing
Entinostat   See Pricing Liposomal compositions of epoxyketone-based proteasome inhibitors Onyx Therapeutics, Inc. (Thousand Oaks, CA)   See Pricing
Entinostat   See Pricing Oxabicycloheptanes and oxabicycloheptenes, their preparation and use Lixte Biotechnology, Inc. (East Setauket, NY)   See Pricing
Entinostat   See Pricing Substituted 6-aminopurines for targeting HSP90 Duke University (Durham, NC)   See Pricing
Entinostat   See Pricing Cyclodextrin complexation methods for formulating peptide proteasome inhibitors Onyx Therapeutics, Inc. (Thousand Oaks, CA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Entinostat

Drugname Country Document Number Estimated Expiration Related US Patent
Entinostat World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   See Pricing
Entinostat Australia 2013292636 2032-07-18   See Pricing
Entinostat Australia 2013292647 2032-07-18   See Pricing
Entinostat Australia 2018201445 2032-07-18   See Pricing
Entinostat Canada 2879139 2032-07-18   See Pricing
Entinostat Canada 2879208 2032-07-18   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Merck
Colorcon
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.